Home / Team
Leadership and advisors
Pentamer Biologics LLC is a preclinical vaccine company in Birmingham, Alabama, developing subunit vaccines against Staphylococcus aureus for both animal and human health.
Why one platform serves both
The same platform serves two health systems, and each one strengthens the other. A live challenge in dairy cattle tests the carrier and the antigens against a real infectious disease in a large outbred animal — evidence a mouse cannot provide. What that trial establishes about the platform carries directly into the human programme, where the target is the nasal and skin colonization that seeds surgical and combat wound infection.
Leadership
Leads company strategy, partnerships, and commercialization across both the animal and human health programs.
Leads operations and program execution across both development tracks.
Advisors
Guides the scientific program and the CTA2/B platform. Professor in the Department of Biological Sciences at Boise State University and inventor on the Pentamer intellectual property.
Formerly Senior Regulatory Review Science Officer at FDA CBER, and VP of Global Regulatory Affairs in biopharma.
30+ years in the global veterinary vaccine industry, including R&D leadership at Boehringer Ingelheim, Merial, and Sanofi Pasteur.
Vaccine development consultant, formerly of PATH (Seattle), advising on scale-up and manufacturing.
Boise State University
The CTA2/B platform was developed in the laboratory of Juliette K. Tinker, PhD, at Boise State University, Boise, Idaho, and is licensed to Pentamer Biologics LLC. The Tinker laboratory is Pentamer's partner institution and primary scientific site.
The CTA2/B platform is protected by five issued U.S. patents covering both preventative and therapeutic applications.
Disclosure: B. Allinson is an officer and equity holder of Pentamer Biologics LLC.